Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β2-Agonist Combined With a Long-Acting Muscarinic or Inhaled Corticosteroid.

CONCLUSIONS: Despite concerns about the CCV effects of LAMA and LABA monotherapy, the LABA/LAMA combination had similar or lower risk of these events in comparison to LABA/ICS. Further studies are recommended to confirm these findings.
PMID: 28677404 [PubMed - as supplied by publisher]

Source: The Annals of Pharmacotherapy - July 1, 2017 Category: Drugs & Pharmacology Authors: Samp JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA Tags: Ann Pharmacother Source Type: research